TAS-102 Provides Survival Benefit in Refractory Colorectal Cancer
the Cancer Therapy Advisor take:
In patients with refractory colorectal cancer, TAS-102 was associated with a significant improvement in overall survival compared with placebo, a study published in the New England Journal of Medicine has shown.
For the double-blind study, researchers enrolled 800 patients with refractory colorectal cancer and randomly assigned them 2:1 to receive TAS-102 or placebo.
Results showed that the median overall survival was 5.3 months and 7.1 months in the placebo and TAS-102 groups, respectively (HR for death = 0.68; 95% CI: 0.58-0.81; P < 0.001).
In regard to safety, the most common adverse events associated with TAS-102 were neutropenia, leukopenia, and febrile neutropenia. One patient died as a result of TAS-102 treatment. Median time to worsening performance status was also 1.7 months longer in the TAS-102 arm than the placebo arm (HR = 0.66; 95% CI: 0.56-0.78; P < 0.001).
TAS-102 is an oral agent that combines trifluridine and tipiracil hydrochloride. Previous studies conducted mostly in Japan that it was effective in the treatment of patients with refractory colorectal cancer.
In patients with refractory colorectal cancer, TAS-102 was associated with a significant improvement in overall survival.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Plastics and Cancer
- Cabozantinib Shows Promising Activity in Osteosarcoma and Ewing Sarcoma
- Real-World Study Shows High Response Rates to T-VEC in Early Metastatic Melanoma
- Using ctDNA to Predict Cancer Recurrence and Guide Therapy Selection
- Atezolizumab and Nab-Paclitaxel Prolonged PFS in Metastatic Triple-Negative Breast Cancer
- Infections in Primary Immune Thrombocytopenia Associated With Low Platelet Count
- Expert Panel Provides Recommendations for Running Trials on Intratumoral Immunotherapy
- Large Acute Myeloid Leukemia Dataset Could Help Identify Targeted Treatments
- Treatment of H. pylori Increased Platelet Count in ITP
- Reclassification of Variants of Uncertain Significance: A Q&A With Theodora Ross MD, PhD